Any serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject’s safety, obtaining informed consent or compliance to the study proceduresXx_NEWLINE_xXPatients with a history of any grade autoimmune disorder are not eligible; asymptomatic laboratory abnormalities (e.g. antinuclear antibody [ANA], rheumatoid factor, altered thyroid function studies) will not render a patient ineligible in the absence of a diagnosis of an autoimmune disorderXx_NEWLINE_xXNo major sensory or motor impairment that would preclude valid cognitive testing (e.g., unresolved posterior fossa syndrome, blindness, poorly controlled seizures/photosensitive epilepsy, psychosis) or a major psychological condition that would preclude completion of the intervention (e.g., significant oppositionality, autism spectrum disorder, severe anxiety or depressive symptoms)Xx_NEWLINE_xXNo history of psychiatric disorders that would preclude participation in the study intervention (e.g. untreated major depression or psychosis, substance abuse, severe personality disorder) or prevent the patient from giving informed consentXx_NEWLINE_xXPatients considered at poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection; examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, extensive bilateral lung disease on high resolution computed tomography scan or any psychiatric disorder that prohibits obtaining informed consentXx_NEWLINE_xXPatient must not have intercurrent organ damage or medical problems that will jeopardize the outcome of therapy (i.e., psychiatric disorder, drug abuse, pregnancy)Xx_NEWLINE_xXPatient must not have an antecedent hematologic disorderXx_NEWLINE_xXParticipants considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection; examples include, but are not limited to, corrected QT interval (QTc) prolongation > 470 msec, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, unstable spinal cord compression (untreated and unstable for at least 28 days prior to study entry), extensive bilateral lung disease with less than 20% predicted lung function by carbon monoxide diffusing capability test (DLCO) (Lung Diffusion Capacity Testing), or any psychiatric disorder that prohibits obtaining informed consentXx_NEWLINE_xXPatients with porphyria or psoriasis are ineligible unless the disease is well controlled and they are under the care of a specialist for the disorder who agrees to monitor the patient for exacerbationsXx_NEWLINE_xXKnown prior history of mania or major psychiatric illness (schizophrenia, bipolar disorder, severe major depression requiring hospitalization, etc.)Xx_NEWLINE_xXAny serious uncontrolled medical disorder or active infection that would impair the subject’s ability to receive investigational product, such as conditions associated with frequent diarrheaXx_NEWLINE_xXPatients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection; examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consentXx_NEWLINE_xXPresence of any serious or unstable concomitant systemic disorder incompatible with the clinical study (e.g., substance abuse, psychiatric disturbance, uncontrolled intercurrent illness including arterial thrombosis, or symptomatic pulmonary embolism)Xx_NEWLINE_xXHas any psychiatric or medical disorder that would preclude safe participation in and/or adherence to the protocolXx_NEWLINE_xXDiagnosis of autoimmune disorder, including RA, SLE, or Sjogren's syndromeXx_NEWLINE_xXParticipant must not have a history of a coagulopathy or a platelet disorder.Xx_NEWLINE_xXHave evidence of any other significant clinical disorder or laboratory finding that, as judged by the investigator, makes it undesirable for the patient to participate in the studyXx_NEWLINE_xXPatients with a genetic disorder of fat metabolismXx_NEWLINE_xXA prospective patient for allogeneic HCT for a malignant hematologic disorderXx_NEWLINE_xXAny other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results\r\n* Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection; examples include, but are not limited to, uncontrolled ventricular arrhythmia, superior vena cava syndrome, extensive bilateral lung disease on high resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consentXx_NEWLINE_xXHas a serious or unstable concomitant systemic disorder incompatible with the clinical study (e.g., substance abuse, uncontrolled psychiatric condition, uncontrolled intercurrent illness including active infection, arterial thrombosis, or symptomatic pulmonary embolism).Xx_NEWLINE_xXPsychiatric disorder or altered mental status precluding informed consent or protocol-related testingXx_NEWLINE_xXPatients must have a histologically confirmed CD20+ lymphoproliferative disease that is related to an immunosuppressed state (e.g., post-transplant lymphoproliferative disorder [PTLD], diffuse large B-cell lymphoma [DLBCL] of the elderly, iatrogenic immunodeficiency-associated lymphoproliferative disorder [LPD]) and for which rituximab monotherapy would be considered to be appropriate frontline therapyXx_NEWLINE_xXParticipants with an unstable major psychiatric disorder, as assessed by study clinician, or a diagnosis of alcohol abuse (more than 5 drinks in a 24 hour period) or substance dependence within the past 1 year (as determined by a standard psychiatric interview) will be excluded unless otherwise approved by the PI or PI’s designeeXx_NEWLINE_xXPatients with an identified familial hyperlipidemia disorderXx_NEWLINE_xXPrimary immunodeficiency disorder or other nonmalignant inherited disease (except Fanconi anemia) treatable by allogeneic HCTXx_NEWLINE_xXKnown coagulopathy, platelet disorder or history of non-drug-induced thrombocytopeniaXx_NEWLINE_xXPatients who are being treated with Valproic Acid for any of its indication (epilepsy, mood disorder) must be excluded or must stop using the medication.Xx_NEWLINE_xXWomen with active liver disease or thromboembolic disorder.Xx_NEWLINE_xXPatients with a known disorder that affects their immune system, such as human immunodeficiency virus (HIV), or an autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy are not eligible; Note: patients that are currently using inhaled, intranasal, ocular, topical or other non-oral or non-intravenous (IV) steroids are not necessarily excluded from the study but need to be discussed with the study chairXx_NEWLINE_xXActive psychiatric disorder which may compromise compliance with the transplant protocol, or which does not allow for appropriate informed consentXx_NEWLINE_xXDONOR: History of a psychiatric disorder which in the opinion of the PI may compromise compliance with the transplant protocol, or which does not allow for appropriate informed consentXx_NEWLINE_xXPatients must NOT have active clinically significant CNS dysfunction (including but not limited to such as uncontrolled seizure disorder, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder)Xx_NEWLINE_xXPatients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consentXx_NEWLINE_xXPsychiatric disorder or a mental deficiency of the patient that is sufficiently severe to make compliance with the treatment unlikely, and making informed consent impossible.Xx_NEWLINE_xXDiagnosis of bipolar disorder, schizophrenia, post-traumatic stress disorder (PTSD) and or adult attention deficit hyperactivity disorder (ADHD)Xx_NEWLINE_xXGeneralized Anxiety Disorder (GAD)-7 scale of 15 or higherXx_NEWLINE_xXSevere gastrointestinal disorderXx_NEWLINE_xXSubjects considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan, history of pneumonitis, or any psychiatric disorder that prohibits obtaining informed consent.Xx_NEWLINE_xXHistory of any renal calculi or hyperoxaluria or any other preexisting renal disorderXx_NEWLINE_xXUncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigator, could interfere with study assessments or compliance.Xx_NEWLINE_xXHistory of any inherited coagulation or platelet function, disorder or ITP, TTP, or HUSXx_NEWLINE_xXAny significant medical condition, including any suggested by screening laboratory findings that, in the opinion of the investigator or sponsor, may place the subject at undue risk from the study, including but not necessarily limited to uncontrolled hypertension and/or diabetes, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease requiring hospitalization within 3 months) or neurological disorder (e.g., seizure disorder active within 3 months).Xx_NEWLINE_xXHistory or presence of any CNS disorder such as a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvementXx_NEWLINE_xXActive or chronic corneal disorder, history of corneal transplantation, active herpetic keratitis, and active ocular conditions requiring ongoing treatment/monitoringXx_NEWLINE_xXHave a serious concomitant systemic disorder.Xx_NEWLINE_xXSubjects must NOT have active clinically significant CNS dysfunction (including but not limited to such as uncontrolled seizure disorder, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination, or movement disorder)Xx_NEWLINE_xXPatients with severe psychiatric (i.e. schizophrenia, bipolar, or borderline personality disorder) or other clinically progressive major medical problems, unless approved by the Investigator.Xx_NEWLINE_xXIntestinal obstruction, uncontrolled gastrointestinal hemorrhage, pulmonary fibrosis, renal failure, liver failure, or cerebrovascular disorderXx_NEWLINE_xXA serious uncontrolled medical disorder or active infection, which would impair the ability of the subject to receive protocol therapyXx_NEWLINE_xXUncontrolled disease-related metabolic disorder (e.g., hypercalcemia);Xx_NEWLINE_xXAny underlying medical or psychiatric condition, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of adverse events. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, superior vena cava syndrome, extensive bilateral lung disease on high-resolution computed tomography scan, uncontrolled seizures or any psychiatric disorder that prohibits obtaining informed consent.Xx_NEWLINE_xXSubjects must NOT have active clinically significant CNS dysfunction (including but not limited to such as uncontrolled seizure disorder, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination, or movement disorder)Xx_NEWLINE_xXActive keratitis or current corneal disorder.Xx_NEWLINE_xXAny serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject’s safety, obtaining informed consent or compliance to the study proceduresXx_NEWLINE_xXSubjects with additional loci of pain above the mid-thoracic level or other pain disorder due to non-cancer etiology.Xx_NEWLINE_xXPatient has a bleeding disorder or a screening platelet count <100×109/L, or requires continuous anticoagulation or bridging anticoagulation during the procedureXx_NEWLINE_xXPatients must not be considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection; examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consentXx_NEWLINE_xXHistory of pre-existing immunodeficiency disorder, autoimmune condition, or chronic infectionXx_NEWLINE_xXPatients should not have an autoimmune disorder that requires active immunosuppressionXx_NEWLINE_xXA serious uncontrolled medical disorder or active infection that would impair their ability to receive study treatmentXx_NEWLINE_xXPatients must NOT have active clinically significant central nervous system (CNS) dysfunction (including but not limited to such as uncontrolled seizure disorder, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorderXx_NEWLINE_xXHistory of neurologic disorder including but not limited to: prior seizure, epilepsy, structural brain abnormality, benign brain tumor, stroke, brain injuries, dementia, movement disorder or other significant CNS abnormalitiesXx_NEWLINE_xXA serious uncontrolled medical disorder or active infection that would impair their ability to receive study treatmentXx_NEWLINE_xXSerious concomitant systemic disorder.Xx_NEWLINE_xXPatients with severe psychiatric (i.e. schizophrenia, bipolar, or borderline personality disorder) or other clinically progressive major medical problems, unless approved by the PI.Xx_NEWLINE_xXPresence of active neurological disorder(s).Xx_NEWLINE_xXPoor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection; examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consentXx_NEWLINE_xXPatients with psoriasis are ineligible unless the disease is well controlled, and they are under the care of a specialist for the disorder who agrees to monitor the patient for exacerbationsXx_NEWLINE_xXPsychiatric disorder that would preclude patients from signing an informed consentXx_NEWLINE_xXPatients with life expectancy of =< 6 months for reasons other than their underlying hematologic/oncologic disorderXx_NEWLINE_xXPatients with corneal epitheliopathy or any eye disorder that may predispose the patients to this condition at the discretion of the ophthalmologistXx_NEWLINE_xXHistory or presence of non-malignant CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvementXx_NEWLINE_xXPatients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection; examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, unstable spinal cord compression (untreated or unstable within at least 28 days prior to registration), superior vena cava syndrome, extensive bilateral lung disease on high-resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consentXx_NEWLINE_xXPapilledema or other active optic nerve disorderXx_NEWLINE_xXCurrent thrombotic or hemorrhagic disorder/event or history of prior event within 6 months of start of screeningXx_NEWLINE_xXAs per self report, participant has major depressive disorder, alcohol or drug dependence andXx_NEWLINE_xXAnti-coagulant therapy, bleeding or clotting disorderXx_NEWLINE_xXHas history of bipolar disorder or major depressionXx_NEWLINE_xXAny serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject’s safety, obtaining informed consent or compliance to the study procedures, in the opinion of the investigatorXx_NEWLINE_xXUnderlying psychiatric disorder requiring pharmacological intervention or a Hospital Anxiety and Depression Scale (HADS) score of 8 or moreXx_NEWLINE_xXNeurological disorder (Parkinson’s disease, dementia, multiple sclerosis)Xx_NEWLINE_xXHave a serious concomitant systemic disorder.Xx_NEWLINE_xXPresence of any serious or unstable concomitant systemic disorder incompatible with the clinical studyXx_NEWLINE_xXPsychiatric disorder or a mental deficiency of the patient that is sufficiently severe to make compliance with the treatment unlikely, and making informed consent impossibleXx_NEWLINE_xXBipolar disorderXx_NEWLINE_xXHistory of ileus or other significant gastrointestinal disorder known to predispose to ileus or chronic bowel hypomotility, for example, gastroparesis, history of extensive abdominal surgeryXx_NEWLINE_xXAny uncontrolled medical or psychiatric disorder that would preclude participation as outlinedXx_NEWLINE_xXBreast cancer survivors with a severe current psychiatric diagnosis (e.g. bipolar disorder)Xx_NEWLINE_xXCurrent diagnosed neurologic disorderXx_NEWLINE_xXPatients with active, uncontrolled psychiatric disorders including: psychosis, major depressive, and bipolar disordersXx_NEWLINE_xXPsychiatric disorder which, per treating physician discretion, may preclude complianceXx_NEWLINE_xXA serious uncontrolled medical disorder or active infection that would impair their ability to receive study treatmentXx_NEWLINE_xXPatients being considered at poor medical risk due to a serious, uncontrolled medical disorder or non-malignant systemic disease.Xx_NEWLINE_xXAny psychiatric disorder that prohibits obtaining informed consentXx_NEWLINE_xXThe patient has a history of uncontrolled hereditary or acquired thrombotic disorderXx_NEWLINE_xXThe subject has a history of, or is reasonably suspected to meet criteria for the diagnosis of a known congenital or acquired disorder causing systemic immunosuppression; or the subject is currently receiving any drug or supplement which is known to be associated with systemic immune suppression including those drugs which are prescribed for solid organ or stem cell transplant, autoimmune/inflammatory disorders, or other related medical conditionsXx_NEWLINE_xXPatients with active, uncontrolled psychiatric disorders include: psychosis, major depression, and bipolar disordersXx_NEWLINE_xXKnown mania-associated psychiatric disorderXx_NEWLINE_xXHistologically confirmed histiocytic disorder or histologic findings compatible with a histiocytic disorder in the context of confirmatory radiologic findingsXx_NEWLINE_xXHistory of clinically significant liver disease, urea cycle disorder, or genetic liver problem caused by a mitochondrial disorder (e.g., Alpers-Huttenlocher syndrome)Xx_NEWLINE_xXAny uncontrolled active medical disorder that would preclude participation as outlinedXx_NEWLINE_xXAny uncontrolled active medical disorder that would preclude participationXx_NEWLINE_xXPatients with life expectancy of =< 6 months for reasons other than their underlying hematologic/oncologic disorderXx_NEWLINE_xXAny uncontrolled medical or psychiatric disorder that would preclude participationXx_NEWLINE_xXSubjects must not have a history of neurodegenerative or central nervous system movement disorderXx_NEWLINE_xXParticipants with prior documented antecedent hematological disorder (AHD)Xx_NEWLINE_xXSymptomatic cognitive or emotive disorder such as untreated schizophrenia, severe untreated depression, anxiety; this is determined by clinical assessmentXx_NEWLINE_xXPatients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection; examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, unstable spinal cord compression (untreated and unstable for at least 28 days prior to study entry), superior vena cava syndrome, extensive bilateral lung disease on high resolution CT scan or any psychiatric disorder that prohibits obtaining informed consentXx_NEWLINE_xXUnstable psychiatric disorder that would render the patient unable to comply with study requirements.Xx_NEWLINE_xXHave a psychiatric disorder(s) or psychosocial circumstance(s) which in the opinion of the primary physician would place the patient at an unacceptable risk from transplantXx_NEWLINE_xXPatients with a mental disorder, psychiatric illness/social or concussion which would inhibit their ability to provide informed consent or prevent compliance with follow-upXx_NEWLINE_xXAny serious/and or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject’s safety, obtaining informed consent or compliance to the study proceduresXx_NEWLINE_xXActive neurologic disorder (i.e. weakness, altered mental status) – peripheral neuropathy alone does not exclude a patientXx_NEWLINE_xXPatients with psoriasis are ineligible unless the disease is well controlled, and they are under the care of a specialist for the disorder who agrees to monitor the patient for exacerbationsXx_NEWLINE_xXAny serious and/or unstable pre-existing medical disorder (aside from malignancy exception), psychiatric disorder, or other conditions that could interfere with subject’s safety, obtaining informed consent or compliance to the study proceduresXx_NEWLINE_xXAny concomitant serious physical illness other than cancer (i.e., immune deficiency disease, bleeding disorder, etc.) within 1 year prior to dosingXx_NEWLINE_xXMyeloid disorder (myelodysplastic syndrome [MDS] with intermediate/high risk features or refractory disease or myeloproliferative disorder; primary or secondary if high-risk features or refractory disease)Xx_NEWLINE_xXPatients with the following mood disorders as judged by the investigator or a psychiatrist, or as a result of patient’s mood assessment questionnaire:\r\n* Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others) or patients with active severe personality disorders (defined according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM- IV]) are not eligible; Note: for patients with psychotropic treatments ongoing at baseline, the dose and the schedule should not be modified within the previous 6 weeks prior to start of study drug\r\n* >= Common Terminology Criteria for Adverse Events (CTCAE) grade 3 anxiety\r\n* Meets the cut-off score of >= 12 in the Patient Health Questionnaire (PHQ)-9 or a cut-off of >= 15 in the Generalized Anxiety Disorder (GAD)-7 mood scale, respectively, or selects a positive response of \1, 2, or 3\ to question number 9 regarding potential for suicidal thoughts in the PHQ-9 (independent of the total score of the PHQ-9)Xx_NEWLINE_xXAny uncontrolled active medical disorder that would preclude participation as outlinedXx_NEWLINE_xXCurrently taking selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), or tricyclic antidepressant (TCA) regimen for treatment of major depressive disorder or generalized anxiety disorder (without approval and involvement of the patient’s treating psychiatrist)Xx_NEWLINE_xXRECIPIENT: History of psychiatric disorder which may compromise compliance with transplant protocol, or which does not allow for appropriate informed consentXx_NEWLINE_xXMATCHED RELATED DONOR: History of psychiatric disorder which in the opinion of the PI may compromise compliance with transplant protocol, or does not allow for appropriate informed consentXx_NEWLINE_xXHAPLOIDENTICAL RELATED DONOR: History of psychiatric disorder which in the opinion of the PI may compromise compliance with transplant protocol, or which does not allow for appropriate informed consentXx_NEWLINE_xXAny other serious uncontrolled medical disorder or active infection that would impair the patient’s ability to receive study treatment (at the discretion of the investigator)Xx_NEWLINE_xXSubjects must not have a history of thromboembolic disorder or cerebral vascular diseaseXx_NEWLINE_xXPatients must not have a history of any immune system disorder, or laboratory abnormality or any condition that could potentially alter immune functionXx_NEWLINE_xXPatients with life expectancy of =< 6 months for reasons other than their underlying hematologic/oncologic disorderXx_NEWLINE_xXSerious uncontrolled medical disorder or uncontrolled active systemic infection or current unstable or decompensated respiratory or cardiac conditions which makes it undesirable or unsafe for the patient to participate in the studyXx_NEWLINE_xXPatients with history of bleeding disorder or with history of spontaneous haemorrhage tumourXx_NEWLINE_xXCorneal epitheliopathy or any eye disorder that may predispose the patients to this conditionXx_NEWLINE_xXAny serious uncontrolled medical disorder that would impair the ability of the subject to receive protocol-driven therapyXx_NEWLINE_xXPatients with life expectancy of =< 6 months for reasons other than their underlying hematologic/oncologic disorderXx_NEWLINE_xXHistory of an active connective tissue disorderXx_NEWLINE_xXPsychiatric disorder that would preclude patients from signing an informed consentXx_NEWLINE_xXPatients with life expectancy of =< 6 months for reasons other than their underlying hematologic/oncologic disorderXx_NEWLINE_xXHistory of psychiatric disorder which may compromise compliance with transplant protocol, or which does not allow for appropriate informed consentXx_NEWLINE_xXHAPLOIDENTICAL DONOR: History of psychiatric disorder which in the opinion of the PI may compromise compliance with transplant protocol, or which does not allow for appropriate informed consentXx_NEWLINE_xXActive psychiatric disorder which may compromise compliance with the treatment protocol, or which does not allow for appropriate informed consent (as determined by principal investigator and/or his designee)Xx_NEWLINE_xXDONOR: History of psychiatric disorder which may compromise compliance with this protocol or which does not allow for appropriate informed consentXx_NEWLINE_xXKnown existing uncontrolled coagulopathy, hemorrhagic disorder, or inability to discontinue Coumadin or Plavix for 5 days prior to each treatment (except for prophylaxis against portacath-associated thrombosis, which does not require cessation of therapy)Xx_NEWLINE_xXHistory of seizure disorder or clinically treated bipolar disorderXx_NEWLINE_xXPatients with severe personality disorder or mental illness that would preclude compliance with the studyXx_NEWLINE_xXBleeding or thrombotic disorder or any prescribed anticoagulant requiring therapeutic international normalized ratio monitoring (eg, warfarin or similar agents) at Screening, or within 6 months before randomization/enrollmentXx_NEWLINE_xXNo history of a coagulation disorderXx_NEWLINE_xXPatients has any of the following mood disorders as judged by the Investigator or a Psychiatrist, or who meets the cut-off score of >= 10 on the Patient Health Questionnaire (PHQ-9) or a cut-off of >= 15 in the Generalized Anxiety Disorder 7-item (GAD-7) mood scale, respectively, or selects a positive response of ‘1, 2, or 3’ to question number 9 regarding potential for suicidal thoughts in the PHQ-9 (independent of the total score of the PHQ-9)\r\n* Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others)\r\n* >= Common Terminology Criteria for Adverse Events (CTCAE) grade 3 anxiety\r\nNote: The psychiatric judgment overrules the mood assessment questionnaire result/investigators judgmentXx_NEWLINE_xXEvidence of end-organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically:Xx_NEWLINE_xXKnown malabsorptive disorderXx_NEWLINE_xXContraindications to use of bupropion (i.e., concurrent use of other forms of bupropion, MAO inhibitors, anti-depressant medication, seizure disorder or any clinical situation that might increase risk for seizures, past head injury, current or prior diagnosis of bulimia or anorexia nervosa; bipolar disorder).Xx_NEWLINE_xXHistory of bipolar disorder.Xx_NEWLINE_xXPatients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection.  Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent.Xx_NEWLINE_xXPatients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection; examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 5 years) myocardial infarction, uncontrolled major seizure disorder, uncontrolled hypertension (blood pressure [BP] ? 160/100), stroke within the past 5 years, uncontrolled diabetes (hemoglobin [hgb] A1C >7), unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consentXx_NEWLINE_xXA history of thromboembolic disorderXx_NEWLINE_xXSerious uncontrolled medical disorder or active infection that would impair the patient's ability to receive study treatment.Xx_NEWLINE_xXAutoimmune disorderXx_NEWLINE_xXSevere organ failures or diseases, including: clinically relevant coronary disease, myocardial infarction or any other relevant cardiovascular disorder within 12 months before study entry, severe psychiatric illness and severe infection.Xx_NEWLINE_xXUnmanaged/uncontrolled mental health disorderXx_NEWLINE_xXUncontrolled non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent.Xx_NEWLINE_xXPatient has any serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with patient’s safety, provision of informed consent, or compliance with the study procedures.Xx_NEWLINE_xXAny serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject’s safety, obtaining informed consent, or compliance to the study proceduresXx_NEWLINE_xXHave a prior history of cancer other than MDS or myeloproliferative disorder, unless the subject has been free of the disease for ? 1 year prior to the start of study treatment.Xx_NEWLINE_xXCurrent addictive or psychiatric disorder which may preclude protocol adherenceXx_NEWLINE_xXThe subject has a history of, or is reasonably suspected to meet criteria for the diagnosis of a known congenital or acquired disorder causing systemic immunosuppression; or the subject is currently receiving any drug or supplement which is known to be associated with systemic immune suppression including those drugs which are prescribed for solid organ or stem cell transplant, autoimmune/inflammatory disorders, or other related medical conditionsXx_NEWLINE_xXPatients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection; examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent and would limit compliance with study requirementsXx_NEWLINE_xXAny serious or uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy.Xx_NEWLINE_xXAny serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject’s safety, obtaining informed consent or compliance to the study procedures, in the opinion of the investigatorXx_NEWLINE_xXFor participants on the BKM120 cohort only: \r\n* Any patient with a history of major depressive episode, bipolar disorder, obsessive/compulsive disorder, schizophrenia, a history of suicide attempt or ideation, or homicide/homicidal ideation as judged by the investigator and/or based on recent psychiatric assessment will not qualify for study participation\r\n* >= CTCAE grade 3 anxiety at the time of study entry regardless of whether the anxiety is being treated with medications\r\n* Patients with the following mood disorders as judged by the investigator or a psychiatrist, or as a result of patient’s mood assessment questionnaire:\r\n** Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others)\r\n** >= CTCAE grade 3 anxiety\r\n** Meets the cut-off score of >= 10 in the Patient Health Questionnaire (PHQ)-9 or a cut-off of >= 15 in the Generalized Anxiety Disorder (GAD)-7 mood scale, respectively, or selects a positive response of “1, 2, or 3” to question number 9 regarding potential for suicidal thoughts in the PHQ-9 (independent of the total score of the PHQ-9)Xx_NEWLINE_xXPresence of any serious or unstable concomitant systemic disorder incompatible with\n             the clinical studyXx_NEWLINE_xXChronic myeloproliferative disorder, i.e. myelofibrosisXx_NEWLINE_xXCurrent or prior HTLV-1 associated inflammatory diseases, including but not limited to myelopathy, uveitis, arthropathy, pneumonitis, or a Sjogren’s disease-like disorderXx_NEWLINE_xXPatient has a Generalized Anxiety Disorder (GAD)-7 mood scale score >= 15Xx_NEWLINE_xXPatient has a medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or others); ), or patients with active severe personality disorders (defined according to Diagnostic and Statistical Manual of Mental Disorders [DSM]- IV) are not eligible; patients who have a history of major depression that is controlled with chronic oral therapy are eligible provided they have no history of inpatient hospitalization, history of documented suicide attempt or ideations, and are managed with one anti-depressant which has not required dose adjustment in 6 weeks; patients with a history of depression who would otherwise be eligible should be evaluated by a mental health professional prior to enrollment if there is any uncertainty regarding the status of their mental health; Note: for patients with psychotropic treatments ongoing at baseline, the dose and the schedule should not be modified within the previous 6 weeks prior to start of study drugXx_NEWLINE_xXSubject has any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of drugs in this protocol or place the subject at undue risk for treatment complicationsXx_NEWLINE_xXPatients with known immunodeficiency disorder, or presumed to be unable to respond to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA 4) monoclonal antibody (mAb)Xx_NEWLINE_xXPatients with relapsed or refractory AML age >= 18 years are also eligible for treatment; patients may have been treated for antecedent hematologic disorder with myeloid growth factors, recombinant erythropoietin, thalidomide, lenalidomide, 5-azacitidine or the 5 day schedule of decitabine; patients who have received the 10 day schedule of decitabine for treatment an antecedent hematologic disorder or AML are not eligibleXx_NEWLINE_xXPatients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection; examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent; evidence of severe or uncontrolled systemic disease or any concurrent condition which, in the investigator's opinion, makes it desirable for the patient to participate in the trial or which would jeopardize compliance with the protocolXx_NEWLINE_xXPatients has any of the following mood disorders as judged by the Investigator or a psychiatrist, or who meets the cut-off score of >= the Patient Health Questionnaire-9 (PHQ-9) or a cut-off of >= 15 in the Generalized Anxiety Disorder 7 (GAD-7) mood scale, respectively, or selects a positive response of ‘1, 2, or 3’ to questions number 9 regarding potential for suicidal thoughts in the PHQ-9 (independent of the total score of the PHQ-9)\r\n* Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others)\r\n* >= Common Terminology Criteria for Adverse Events (CTCAE) grade 3 anxiety\r\n* Note: the psychiatric judgment overrules the mood assessment questionnaire result or the investigators judgmentXx_NEWLINE_xXPatients with a history of a psychiatric disorder that may interfere with the understanding and compliance with this protocol and the required follow upXx_NEWLINE_xXAny known pre-existing autoimmune disorderXx_NEWLINE_xXSerious psychiatric condition or addictive disorderXx_NEWLINE_xXPatients with a known coagulation disorder are excluded; patients with a first-degree relative with a history of venous thrombosis before age 50 years (yrs) or an arterial thrombosis before age 40 yrs must have the following testing performed prior to enrollment to exclude a heritable disorder; patients with a suspected disorder will be excludedXx_NEWLINE_xXPrimary immunodeficiency disorder or other nonmalignant inherited disease (except aplastic anemia and Fanconi anemia) treatable by allogeneic HCTXx_NEWLINE_xXHistory of psychiatric disorder which may compromise compliance with transplant protocol, or which does not allow for appropriate informed consentXx_NEWLINE_xXHistory of psychiatric disorder (e.g. depression; suicidal ideation; psychosis)Xx_NEWLINE_xXHistory of psychiatric disorder (e.g. depression)Xx_NEWLINE_xXHistory of autoimmune disorder (e.g. hepatitis)Xx_NEWLINE_xXAny significant medical condition, including any suggested by screening laboratory findings that, in the opinion of the investigator or sponsor, may place the subject at undue risk from the study, including but not necessarily limited to uncontrolled hypertension and/or diabetes, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease requiring hospitalization within 6 months) or neurological disorder (e.g., seizure disorder active within 6 months)Xx_NEWLINE_xXSignificant psychiatric or neurologic disorder which would compromise participation in the studyXx_NEWLINE_xXPresence of any serious or unstable concomitant systemic disorder incompatible with the clinical studyXx_NEWLINE_xXSerious concurrent uncontrolled medical disorderXx_NEWLINE_xXThe presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of drugs in this protocol or place the subject at undue risk for treatment complicationsXx_NEWLINE_xXHistory of coagulopathy, platelet disorder or history of non-drug induced thrombocytopeniaXx_NEWLINE_xXAny serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject’s safety, obtaining informed consent or compliance to the study proceduresXx_NEWLINE_xXAny other condition which, in the opinion of the Investigator, might impair the subject's tolerance of trial treatment, the safety of the individual subject or the outcome of the trial. (including but not limited to: history of major depressive episode, bipolar disorder, obsessive-compulsive disorder, schizophrenia, suicidal attempt or ideation, homicidal ideation, or >= Common Terminology Criteria for Adverse Events [CTCAE] Grade 3 anxiety)Xx_NEWLINE_xXHas any of the following medical conditions: uncontrolled diabetes, psychiatric disorder (including dementia) that prevents compliance with protocol, uncontrolled seizures, newly diagnosed deep vein thrombosis, active systemic infection that is likely to interfere with study procedure or resultsXx_NEWLINE_xXThrombocytopenia secondary to other possible causes, including medication(s), congenital disorder(s), immune disorder(s), or microvascular disorder(s)Xx_NEWLINE_xXNo autoimmune disorder that requires active immunosuppressionXx_NEWLINE_xXPatients with psoriasis are ineligible unless the disease is well controlled and they are under the care of a specialist for the disorder who agrees to monitor the patient for exacerbationsXx_NEWLINE_xXHave a history of uncontrolled hereditary or acquired thrombotic disorder.Xx_NEWLINE_xXSerious uncontrolled medical disorderXx_NEWLINE_xXAny uncontrolled active medical disorder that would preclude participationXx_NEWLINE_xXHistory of Wilson’s disease or other copper-metabolism disorderXx_NEWLINE_xXAny uncontrolled active medical disorder that would preclude participation as outlinedXx_NEWLINE_xXConcurrent corneal disorder or ophthalmologic condition making subject unsuitableXx_NEWLINE_xXAny gastrointestinal (GI) disorder or liver diseaseXx_NEWLINE_xXActive gastrointestinal/malabsorption disorder at the discretion of the principal investigator\r\n* Inflammatory bowel disease\r\n* Celiac disease\r\n* Chronic pancreatitis\r\n* Chronic diarrhea or vomiting\r\n* Active eating disorderXx_NEWLINE_xXA serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapyXx_NEWLINE_xXPatients with a known or suspected urea cycle or other metabolic disorder are not eligibleXx_NEWLINE_xXUncontrolled endocrine disorder. Patients who are on endocrine replacement therapy must be on a stable dose.Xx_NEWLINE_xXHistory of a calcium/phosphate homeostasis disorderXx_NEWLINE_xXCurrent evidence of corneal disorder/keratopathyXx_NEWLINE_xXAny patient with a history of major depressive episode, bipolar disorder, obsessive/compulsive disorder, schizophrenia, a history of suicide attempt or ideation, or homicide/homicidal ideation as judged by the investigator and/or based on recent psychiatric assessment may not participate in this study without discussion with and agreement of the study principal investigator (PI)Xx_NEWLINE_xXHas a known blood clotting disorder requiring treatmentXx_NEWLINE_xXPatient has a medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, homicidal ideation (e.g. risk of doing harm to self or others)Xx_NEWLINE_xXHas uncontrolled disease-related metabolic disorderXx_NEWLINE_xXPatients with corneal epitheliopathy or any eye disorder that may predispose the patients to this condition at the discretion of the investigator in consultation with the ophthalmologist.Xx_NEWLINE_xXDiagnostic and Statistical Manual of Mental Disorders (DSM)-IV diagnoses for psychotic disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), major depressive disorder within the last 3 months, substance dependence within the last 3 months with the exception of nicotine and marijuana dependenceXx_NEWLINE_xXAny serious uncontrolled medical disorder or active infection that would impair the subject’s ability to receive investigational product, such as conditions associated with frequent diarrheaXx_NEWLINE_xXKnown history of an autoimmune disorderXx_NEWLINE_xXHave a serious concomitant systemic disorder or significant cardiac disease.Xx_NEWLINE_xXActive liver disease, for example, due to autoimmune hepatic disorder, or sclerosing cholangitisXx_NEWLINE_xXOther conditions which could jeopardize the subject's ability to comply with the protocol including but not limited to dementia, psychosis, or other major psychiatric disorder.Xx_NEWLINE_xXParticipants with active malignant relapse or recrudescence of their prior hematologic disorderXx_NEWLINE_xXCurrent major depression or another major psychiatric disorder as described in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (use of central nervous system [CNS] active medications (e.g. antidepressants) will be permitted, provided dosing has been stable for at least 3 months)Xx_NEWLINE_xXPatient has a Generalized Anxiety Disorder (GAD)-7 mood scale score >= 15Xx_NEWLINE_xXPatient has a medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or others)Xx_NEWLINE_xXParticipant has received treatment with cytarabine for a pre-existing myeloid disorder.Xx_NEWLINE_xXPatients with the following mood disorders as judged by the Investigator or a psychiatrist, or as a result of patient’s mood assessment questionnaire:\r\n* Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others) or patients with active severe personality disorders (defined according to Diagnostic and Statistical Manual [DSM]-IV) are not eligible; Note: for patients with psychotropic treatments ongoing at baseline, the dose and the schedule should not be modified within the previous 6 weeks prior to start of study drug\r\n* >= Common Terminology Criteria for Adverse Events (CTCAE) grade 3 anxiety \r\n* Meets the cut-off score of >= 12 in the Patient Health Questionnaire 9-item (PHQ-9) or a cut-off of >= 15 in the Generalized Anxiety Disorder 7-item (GAD-7) mood scale, respectively, or selects a positive response of “1, 2, or 3” to question number 9 regarding potential for suicidal thoughts in the PHQ-9 (independent of the total score of the PHQ-9)Xx_NEWLINE_xXHaving a history or presence of a significant psychiatric disorder or any other condition that, in the investigator’s judgment, would interfere with participation in the trialXx_NEWLINE_xXPatients with active moderate or severe major mood or psychiatric disorder as judged by the investigator, primary care physician, counselor, psychiatrist, or as a result of the patient‘s mood assessment questionnaire that may interfere with the ability to comply with the trial; in addition, given the prior mood-associated toxicities, patients with a history of psychiatric hospitalization within the past 5 years, electroconvulsive therapy (ECT) within the past 5 years, or whose psychiatric condition has been unstable within 2 months prior to study enrollment requiring addition or change of psychotropic medications are not eligible; examples include, but are not limited to:\r\n* Medically documented history of or active major depressive episode requiring inpatient or intensive outpatient therapy, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or active ideation, or homicidal ideation (immediate risk of doing harm to others); patients under the care of a primary care physician who are treated with one oral agent and who have not required dose adjustments or new medications within 2 months prior to study enrollment and who otherwise meet eligibility requirements may be enrolled\r\n* >= Common Terminology for Adverse Events (CTCAE) version 4.0 grade 3 anxiety\r\n* Patients meeting the cutoff score of >= 12 in the Patient Health Questionnaire-9 (PHQ-9) or a cut-off of >= 15 in the Generalized Anxiety Disorder-7 (GAD-7) mood scale, respectively, or who select a positive response of \1, 2, or 3\ to question number 9 regarding potential for suicidal thoughts in the PHQ-9 (independent of the total score of the PHQ-9) are not eligibleXx_NEWLINE_xXKnown history of an autoimmune disorderXx_NEWLINE_xXPsychiatric disorder that would preclude patients from signing an informed consentXx_NEWLINE_xXPatients with life expectancy of =< 6 months for reasons other than their underlying hematologic/oncologic disorderXx_NEWLINE_xXAny serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject’s safety, obtaining informed consent or compliance to the study procedures, in the opinion of the investigatorXx_NEWLINE_xXGenetic disorder predisposing patient to skin cancers or radiation sensitivity (basal cell nevus syndrome, xeroderma pigmentosum, ataxia telangiectasia mutans)Xx_NEWLINE_xXHistory of bipolar disorderXx_NEWLINE_xXHistory of eating disorder such as anorexia or bulimiaXx_NEWLINE_xXPresence of any serious and/or unstable pre-existing medical disorder, psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study proceduresXx_NEWLINE_xXPatients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active/uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent.Xx_NEWLINE_xXHistory or presence of clinically relevant CNS pathology such as epilepsy, generalized seizure disorder, paresis, aphasia, stroke with current neurologic sequelae, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, or psychosisXx_NEWLINE_xXSerious uncontrolled medical disorder or active infection which would impair the ability of the subject to receive protocol therapy or whose control would be jeopardized by protocol therapyXx_NEWLINE_xXDue to risk of disease exacerbation patients with psoriasis are ineligible unless the disease is well controlled and they are under the care of a specialist for the disorder who agrees to monitor the patient for exacerbationsXx_NEWLINE_xXPsychiatric disorder or altered mental status precluding informed consent or protocol-related testingXx_NEWLINE_xXHistory of psychiatric disorder which may compromise compliance with the protocol or which does not allow for appropriate informed consentXx_NEWLINE_xXPatients with the following mood disorders as judged by the Investigator or a psychiatrist, or as a result of patient’s mood assessment questionnaire (treating physician to decide on whether to administer questionnaire):\r\n* Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others) or patients with active severe personality disorders (defined according to Diagnostic and Statistical Manual of Mental Disorders [DSM]-IV) are not eligible; Note: for patients with psychotropic treatments ongoing at baseline, the dose and the schedule should not be modified within the previous 6 weeks prior to start of study drug\r\n* >= Common Terminology Criteria for Adverse Events (CTCAE) version 4 (v4) grade 3 anxiety\r\n* Meets the cut-off score of >= 10 in the Patient Health Questionnaire 9 (PHQ-9) or a cut-off of >= 15 in the Generalized Anxiety Disorder 7 (GAD-7) mood scale, respectively, or selects a positive response of “1, 2, or 3” to question number 9 regarding potential for suicidal thoughts in the PHQ-9 (independent of the total score of the PHQ-9)Xx_NEWLINE_xXSignificant gastrointestinal disorder(s), in the opinion of the Principal Investigator, (e.g., Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection)Xx_NEWLINE_xXUncontrolled thrombotic or hemorrhagic disorderXx_NEWLINE_xXAny uncontrolled active medical disorder that would preclude participation as outlinedXx_NEWLINE_xXAny serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures, in the opinion of the investigatorXx_NEWLINE_xXEvidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the trialXx_NEWLINE_xXHistory of Wilson's disease or other copper-metabolism disorderXx_NEWLINE_xXPatients with known or suspected brain metastases, carcinomatous meningitis, uncontrolled seizure disorder, active intracranial bleeding or active neurologic disorder are excludedXx_NEWLINE_xXAny active or chronic corneal disorder and Sjogren's syndrome.Xx_NEWLINE_xXSerious concomitant systemic disorderXx_NEWLINE_xXAntecedent hematological disorder (AHD)Xx_NEWLINE_xXThe patient has a psychiatric, addictive, neurological or other disorder that compromises the ability to give informed consent or comply with study requirementsXx_NEWLINE_xXHistory of serious chronic mental disorder or drug-abuse accompanied by documented problems of compliance with therapeutic programsXx_NEWLINE_xXHistory of psychiatric disorder which may compromise compliance with transplant protocol, or which does not allow for appropriate informed consentXx_NEWLINE_xXKnown immunosuppression (i.e. chronic steroid use) or autoimmune disorderXx_NEWLINE_xXA serious uncontrolled medical disorder or active infection that would impair their ability to receive study treatmentXx_NEWLINE_xXFor Arms A, C or D, patients with the following mood disorders as judged by the investigator or a psychiatrist, or as result of patient’s mood assessment questionnaire:\r\n* Medically documented history of major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others) or patients with active severe personality disorders (defined according to Diagnostic and Statistical Manual of Mental Disorders [DSM]-IV); NOTE: for patients with psychotropic treatments ongoing at baseline, the dose and schedule should not be modified within the previous 6 weeks prior to D1 of treatment with BKM120\r\n* >= Common Terminology Criteria for Adverse Events (CTCAE) grade 3 anxiety \r\n* At screening, meets the cut-off score of >= 10 in the Patient Health Questionnaire (PHQ-9) or a cut-off of >= 15 in the Generalized Anxiety Disorder (GAD-7) mood scale, respectively, or selects a positive response of 1, 2 or 3 to question number 9 regarding potential for suicidal thoughts in the PHQ-9 (independent of the total score of the PHQ-9) will be excluded from the study unless overruled by the psychiatric assessment\r\n* Note: The psychiatric judgment overrules the mood assessment questionnaire result/investigator's judgmentXx_NEWLINE_xXPrevious history of primary platelet disorder or bleeding disorderXx_NEWLINE_xXAny psychiatric or cognitive disorder that would limit the understanding or rendering of informed consent and/or compromise compliance with the requirements of this protocolXx_NEWLINE_xXNo medical disorder that increases risks of radiation or temozolomide (TMZ) chemotherapy; no uncontrolled infection; no known positivity for human immunodeficiency virus (HIV); no other disorder limiting expected survival to < 5 yearsXx_NEWLINE_xXHistory of psychiatric disorder which may compromise complianceXx_NEWLINE_xXSignificant gastrointestinal disorder with diarrhea as major symptomXx_NEWLINE_xXHistory of psychiatric disorder which may compromise compliance with transplant protocol, or which does not allow for appropriate informed consent (as determined by principal investigator or lead associate investigator)Xx_NEWLINE_xXConsidered a poor medical risk due to a serious uncontrolled disorderXx_NEWLINE_xXPre-existing severe psychiatric condition or a history of a psychiatric disorder requiring hospitalization or a history of suicidal ideation or attemptXx_NEWLINE_xXPatients with active, uncontrolled psychiatric disorders including: psychosis, major depression, and bipolar disordersXx_NEWLINE_xXAny serious/and or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject’s safety, obtaining informed consent or compliance to the study proceduresXx_NEWLINE_xXPatient has a history of autoimmune disorder or immune deficiency disorderXx_NEWLINE_xXSubjects known to have an uncontrolled thyroid disorder.Xx_NEWLINE_xXHistory of pre-existing post-traumatic stress disorder (PTSD)Xx_NEWLINE_xXHistory of major psychiatric disorder including use of anti-depressive medications, mood stabilizers, or anti-psychotic drugsXx_NEWLINE_xXHas known psychiatric disorder that would interfere with fulfilling the requirements of the studyXx_NEWLINE_xXHistory or presence of clinically relevant CNS pathology such as epilepsy, generalized seizure disorder, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosisXx_NEWLINE_xXPresence of any serious or unstable concomitant systemic disorder incompatible with the clinical studyXx_NEWLINE_xXSignificant gastrointestinal disorder(s), in the opinion of the principal investigator (e.g., Crohn’s disease, ulcerative colitis, extensive gastric resection)Xx_NEWLINE_xXSubject has concurrent corneal disorder or any ophthalmologic condition that makes the subject unsuitable for study participation (e.g., advanced cataracts, glaucoma).Xx_NEWLINE_xXHistory of or active systemic autoimmune disorder or immunodeficiency syndromesXx_NEWLINE_xXPsychiatric disorder that would preclude patients from signing an informed consentXx_NEWLINE_xXPatients with life expectancy of =< 6 months for reasons other than their underlying hematologic/oncologic disorder or complications there fromXx_NEWLINE_xXActive joint inflammation or other immune disorder involving joints (osteoarthritis is not exclusionary)Xx_NEWLINE_xXSubject has concurrent corneal disorder or any ophthalmologic condition which makes the subject unsuitable for study participation .Xx_NEWLINE_xXActive joint inflammation or history of inflammatory arthritis or other immune disorder involving jointsXx_NEWLINE_xXPatients with the following mood disorders as judged by the Investigator or a psychiatrist, or as a result of patient’s mood assessment questionnaire:\r\n* Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others)\r\n* >= Common Terminology Criteria for Adverse Events (CTCAE) grade 3 anxiety\r\n* Meets the cut-off score of >= 12 in the Patient Health Questionnaire (PHQ)-9 or a cut-off of >= 15 in the Generalized Anxiety Disorder 7-item (GAD-7) mood scale, respectively, or selects a positive response of “1, 2, or 3” to question number 9 regarding potential for suicidal thoughts in the PHQ-9 (independent of the total score of the PHQ-9)Xx_NEWLINE_xXDiagnosis of a nonmalignant disorder considered treatable by HCT.Xx_NEWLINE_xXNote: patients with hyperbilirubinemia clinically consistent with an inherited disorder of bilirubin metabolism (e.g., Gilbert syndrome) will be eligible at the discretion of the treating physician and/or the principal investigatorXx_NEWLINE_xXGrade 3 or 4 eye disorder at study entry, unless stable and longstanding (>3 months) and unlikely to interfere with protocol-required ophthalmology assessments.Xx_NEWLINE_xXHistory of psychiatric disorder which may compromise compliance with the protocol or which does not allow for appropriate informed consentXx_NEWLINE_xXThe presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complicationsXx_NEWLINE_xXHistory of therapy for an autoimmune disorderXx_NEWLINE_xXOther ongoing, uncontrolled illnesses (including HIV infection and active hepatitis A, B, or C), psychiatric disorder, or social situation that would prevent good care on this studyXx_NEWLINE_xXMedically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or others), or patients with active severe personality disorders (defined according to DSM- IV).Xx_NEWLINE_xXPrevious diagnosis of bipolar disorderXx_NEWLINE_xXSerious uncontrolled medical disorder, or active infection, that would impair the ability of the patient to receive protocol therapy.Xx_NEWLINE_xXPost-transplant lymphoproliferative disorderXx_NEWLINE_xXSerious or uncontrolled medical disorder (including infection or cardiovascular disease) or dementia or other serious psychiatric conditionXx_NEWLINE_xXEpstein-Barr virus (EBV) post-transplant lymphoproliferative disorderXx_NEWLINE_xXHistory or presence of CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvementXx_NEWLINE_xXEvidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trialXx_NEWLINE_xXMedically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others).Xx_NEWLINE_xXMedically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or others), or patients with active severe personality disorders.Xx_NEWLINE_xXHistory of psychiatric disorder which may compromise compliance with the protocol or which does not allow for appropriate informed consentXx_NEWLINE_xXHave preexisting Grade ?2 skin disorder (for example, erythema, dermatitis).Xx_NEWLINE_xXHistory or suspicion of a congenital or acquired coagulation disorder.Xx_NEWLINE_xXParticipants with known coagulopathy, platelet disorder or history of non-drug-induced thrombocytopeniaXx_NEWLINE_xXPresence of serious or unstable concomitant systemic disorder incompatible with the clinical study (eg, substance abuse; uncontrolled intercurrent illness including active infection; arterial thrombosis; unstable respiratory, hepatic, renal or cardiac disease; and other active malignancy)Xx_NEWLINE_xXMajor concomitant medical illness inclusive of severe chronic obstructive pulmonary disease, multiple sclerosis, symptomatic coronary artery disease, heart failure, recent major cerebrovascular accident, brittle diabetes, renal dialysis, end stage liver disease, labile hypertension, or any autoimmune disorderXx_NEWLINE_xXUncooperative patients, or patients who are incapable of following directions (for example, as a consequence of a neurological or psychiatric disorder).Xx_NEWLINE_xXAny serious, uncontrolled medical disorder that would impair the ability of the subject to receive protocol driven therapyXx_NEWLINE_xXHistory of Wilson's disease or other copper-related metabolic disorderXx_NEWLINE_xXUncontrolled depression or other major psychiatric disorderXx_NEWLINE_xXThe presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complicationsXx_NEWLINE_xXPatients with a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies.Xx_NEWLINE_xXPsychiatric disorder or social or geographic situation that would preclude study participation.Xx_NEWLINE_xXPsychiatric disorder that may interfere with consent and/or protocol compliance.Xx_NEWLINE_xXPART I: Participants with evidence of a significant psychiatric disorder by history/examination that would prevent completion of the study will not be allowed to participateXx_NEWLINE_xXPART II: Participants with evidence of a significant psychiatric disorder by history/examination that would prevent completion of the study will not be allowed to participateXx_NEWLINE_xXActive joint inflammation or history of inflammatory arthritis or other immune disorder involving the jointsXx_NEWLINE_xXPatients with a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studiesXx_NEWLINE_xXAny prior or current malignancy or myeloproliferative or immunodeficiency disorder.Xx_NEWLINE_xXAny prior or current malignancy or myeloproliferative disorder.Xx_NEWLINE_xXMentally incapacitated or has a significant emotional or psychiatric disorderXx_NEWLINE_xXFollowing mood disorders as judged by the investigator and/or symptom management service co-investigator, or as a result of patient’s mood assessment questionnaire:\r\n* Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others)\r\n* Current >= Common Terminology Criteria for Adverse Events (CTCAE) grade 3 anxiety\r\n* Meets the cut-off score of >= 10 in the Patient Health Questionnaire-9 (PHQ-9) or a cut-off of >= 15 in the Generalized Anxiety Disorder 7-item (GAD-7) mood scale, respectively, or selects a positive response of “1, 2, or 3” to question number 9 regarding potential for suicidal thoughts in the PHQ-9 (independent of the total score of the PHQ-9) will be excluded from the studyXx_NEWLINE_xXDiagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies) of Screening visitXx_NEWLINE_xXPoor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, uncontrolled hypertension, or any psychiatric disorder that prohibits obtaining informed consentXx_NEWLINE_xXPoor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, uncontrolled hypertension, or any psychiatric disorder that prohibits obtaining informed consentXx_NEWLINE_xXSignificant psychiatric or neurologic disorder which would compromise participation in the studyXx_NEWLINE_xXLifetime history of any DSM-IV-TR mood or psychotic disorder (e.g., major depressive disorder, bipolar disorder, schizophrenia)Xx_NEWLINE_xXCurrent unstable major medical disorderXx_NEWLINE_xXMedically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others)Xx_NEWLINE_xXMyeloproliferative disorder (MPD)Xx_NEWLINE_xXPsychiatric disorder, altered mental status precluding informed consent or necessary testingXx_NEWLINE_xXPatients with the following mood disorders as judged by the Investigator or a psychiatrist, or as result of patient's mood assessment questionnaire:\r\n* Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others)\r\n* >= Common Terminology Criteria for Adverse Events (CTCAE) grade 3 anxiety\r\n* At screening, mood rating scores of >= 10 on Patient Health Questionnaire (PHQ)-9 and/or >= 15 on Generalized Anxiety Disorder Scale (GAD)-7, unless overruled by psychiatrist's assessment\r\n* Patient selects a response of \1, 2, or 3\ for question 9 on PHQ-9 questionnaire regarding potential for suicidal thoughts or ideation (independent of the total score of the PHQ-9)\r\n* NOTE: the psychiatric judgment overrules the mood assessment questionnaire result/investigators judgment; if mood rating scores do not meet eligibility criteria and/or the investigator deems that a patient has mood disorder that renders the patient ineligible, that patient may not be registered to the study unless there is a subsequent psychiatric clinic consultation in which the psychiatrist overrules the mood assessment questionnaire result/investigator judgmentXx_NEWLINE_xXThe presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complicationsXx_NEWLINE_xXHistory of psychiatric disorder which may compromise compliance with transplant protocol, or which does not allow for appropriate informed consent (as determined by principal investigator or study chairman)Xx_NEWLINE_xXDONOR: History of psychiatric disorder which may compromise compliance with transplant protocol, or which does not allow for appropriate informed consentXx_NEWLINE_xXAny serious uncontrolled, medical or psychological disorder that would impair the ability of the patient to receive therapyXx_NEWLINE_xXPresence of a serious uncontrolled medical disorder.Xx_NEWLINE_xXDementia, altered mental status, or any other medical condition or disorder that would prohibit the understanding or rendering of assent (if applicable), or ability to comply with study procedures.Xx_NEWLINE_xXEvidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial.Xx_NEWLINE_xXHave a known major sleep disorder documented by prior diagnosis, such as: a) sleep disordered breathing b) narcolepsy c) periodic limb movement disorder d) parasomniasXx_NEWLINE_xXNewly Diagnosed Secondary AML defined as having a history of an antecedent hematologic disorder (myelodysplastic syndromes [MDS], myeloproliferative disease [MPD]or history of cytotoxic treatment for non-hematologic malignancy)Xx_NEWLINE_xXHistory of Wilson's disease or other copper-related metabolic disorderXx_NEWLINE_xXPatient has a General Anxiety Disorder (GAD)-7 mood scale score >= 15Xx_NEWLINE_xXPatient has a medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or others), or patients with active severe personality disorders (defined according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV]) are not eligible; Note: for patients with psychotropic treatments ongoing at baseline, the dose and the schedule should not be modified within the previous 6 weeks prior to start of study drugXx_NEWLINE_xXDiagnosis of depression, major depressive disorder (MDD), suicidal ideations or anxiety disorders in the past 5 years per the medical chart based on Diagnostic and Statistical Manual (DSM) IV diagnosesXx_NEWLINE_xXPatients with active bipolar disorderXx_NEWLINE_xXHistory of or currently taking medications for attention deficit hyperactivity disorder, severe anxiety disorder, schizophrenia, or substance abuse by patient record and/or self-reportXx_NEWLINE_xXActive or a history of Tourette’s syndrome or tic disorderXx_NEWLINE_xXNo active untreated clinically significant psychiatric condition (psychosis, bipolar disorder, or depression)Xx_NEWLINE_xXPatients with psychiatric, addictive, or any disorder that would prevent compliance with protocol requirementsXx_NEWLINE_xXMajor psychiatric disorder, such as schizophrenia, bipolar disorder, or untreated depression (treatment for depression is defined as current therapy with antidepressant medication or cognitive behavioral therapy [CBT])Xx_NEWLINE_xXHistory of current oropharyngeal dysphagia unrelated to cancer diagnosis (e.g. dysphagia due to underlying neurogenic disorder)Xx_NEWLINE_xXPresence of cognitive impairment disorder (i.e. delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection, as detected during the ICCAN intake processXx_NEWLINE_xXParticipants with a documented history of genetic predisposition for thrombosis (anti-phospholipid antibody syndrome, antithrombin [AT]-III deficiency, etc.), platelet disorder or bleeding disorderXx_NEWLINE_xXHistory of major psychiatric condition (e.g. psychosis) in parent or child; severe neurodevelopmental disorder in child (e.g. Down's syndrome)Xx_NEWLINE_xXSelf-reported history of bipolar disorder or manic episodes (which is a contra-indication for light treatment)Xx_NEWLINE_xXHave an active serious mental illness (e.g., schizophrenia, bipolar disorder) as indicated by medical recordsXx_NEWLINE_xXHave a diagnosed sleep disorder (i.e., obstructive sleep apnea or narcolepsy)Xx_NEWLINE_xXMajor mental illness (e.g., schizophrenia, psychotic disorder)Xx_NEWLINE_xXHistory of known bleeding disorder (i.e. disseminated intravascular coagulation or clotting factor deficiency);Xx_NEWLINE_xXSerious accompanying cardiac disorderXx_NEWLINE_xXSerious accompanying cardiac disorder.Xx_NEWLINE_xXNo history of cognitive disorderXx_NEWLINE_xXNo history of mood disorderXx_NEWLINE_xXHave a current diagnosis of seasonal affective disorder or substance abuseXx_NEWLINE_xXHistory of bipolar disorder diagnosisXx_NEWLINE_xXCurrent diagnosis of a major psychiatric disorder (e.g., schizophrenia, bipolar disorder)Xx_NEWLINE_xXHistory of eating disorder (ever uncontrolled or any within the last two years)Xx_NEWLINE_xXMeet Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-V) criteria for current major psychiatric illness, such as bipolar disorder, major depression, active suicidal intent, or psychosis that could be exacerbated by the administration of cannabisXx_NEWLINE_xXMeet criteria for major neurological disorder, such as mild cognitive impairment or neurodegenerative disorders (such as movement disorders, dementia), that could be exacerbated by the administration of cannabisXx_NEWLINE_xXSubjects with a history of substance use disorder other than nicotine, such an opiate use disorderXx_NEWLINE_xXPsychiatric (untreated or poorly controlled schizophrenia, major depression, or bipolar disorder), or communication (language) barrier that would preclude accurate assessment of postoperative pain and/or ability to answer questionnaires (need to be able to read, comprehend, and answer questions)Xx_NEWLINE_xXHistory of bipolar disorder or manic episodes (which is a contra-indication for light treatment)Xx_NEWLINE_xXDocumented attention deficit hyperactivity disorder (ADHD) predating cancer diagnosisXx_NEWLINE_xXThe following exclusion criteria will avoid the possibility of preexisting muscle impairment: history of congenital myopathies; neurologic disorder involving sequelae of spinal derangement; disk disease; tremor and rigidityXx_NEWLINE_xXAny of the following: diagnosis of schizophrenia or bipolar disorder made by a physician, seizure disorder, pacemaker, hearing aids, any metal implanted in the head, or the presence of other known current untreated causes of fatigue such as anemia (defined as hemoglobin [Hgb] < 10 g/dL within 3 months of study enrollment) or untreated hypothyroidismXx_NEWLINE_xXCRP must be >= 3 mg/l in the absence of any other more likely cause of increased CRP like an infection or an autoimmune disorderXx_NEWLINE_xXA significant anxiety disorderXx_NEWLINE_xXPATIENT: No evidence of thought disorder, delusions, or active suicidal ideation is observed or reportedXx_NEWLINE_xXPATIENT: Evidence of thought disorder, delusions, hallucinations, or suicidal ideationXx_NEWLINE_xXCAREGIVER: Evidence of thought disorder, delusions, hallucinations, or suicidal ideationXx_NEWLINE_xXHaving a psychotic disorder or the presence of another psychiatric condition (e.g., severe depression [i.e., > 19 on the Patient Health Questionnaire-9 [PHQ-9]], suicidal ideation) or cognitive impairment (e.g., severe dyslexia, traumatic brain injury) limiting ability to give consent and/or participate fully in the studyXx_NEWLINE_xXPatients who have a cognitive disorder which impacts the ability to follow directions or adhere to safety rules; this will be determined by the physical therapist by assessing whether a neurological disorder or musculoskeletal disorder would prevent the patient from safely exercisingXx_NEWLINE_xXPatients who have a neurological or structural disorder which would impact use of exercise equipment; this will be determined by the physical therapist by assessing whether a neurological disorder or musculoskeletal disorder would prevent the patient from safely exercisingXx_NEWLINE_xXSignificant uncontrolled psychiatric disorder (e.g. psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (e.g. dementia, cognitive impairment) which the treating clinician believes prohibits informed consent or participation in the studyXx_NEWLINE_xXSubjects with bipolar disorder that have experienced a manic episode within 6 months of study entry will be excluded or at the principal investigator (PI)’s discretionXx_NEWLINE_xXSurvivors who report ever being diagnosed with bipolar disorder will be excludedXx_NEWLINE_xXAs per self-report and/or medical record history of diagnosed neurological illness including seizure disorder, a dementing condition, or other neurological illness (multiple sclerosis, history of cerebrovascular accident, etc.)Xx_NEWLINE_xXParticipants with a history of treated or untreated schizophrenia or bipolar disorder as assessed by self-report and review of medical historyXx_NEWLINE_xXAs per self report or as documented in the medical record, current untreated (e.g. no medication, no therapy) major psychiatric disorder (schizophrenia, major depression); patients diagnosed with a major psychiatric disorder will be reviewed by the study principal investigator (PI) to determine eligibility prior to consentXx_NEWLINE_xXMajor mental illness (e.g., schizophrenia, major depressive disorder)Xx_NEWLINE_xXPatient has serious psychiatric condition (e.g., bipolar disorder, schizophrenia or other psychosis, bulimia or anorexia nervosa, suicide attempt within 6 months or current active suicidal ideation) that would compromise the patient’s ability to complete the study, at the discretion of the investigatorXx_NEWLINE_xXAs per self-report, a lifetime history of bipolar disorder, schizophrenia, or schizoaffective disorderXx_NEWLINE_xXIf participating in optional biospecimen collection; as per self-report, has medical conditions that affect the immune system and would confound immune evaluation (e.g., autoimmune disorder, inflammatory disease; uncontrolled thyroid disease; active infection; myocardial infarction or stroke in the last 6 months; type I diabetes; acute hepatitis; recent vaccination for viral disease)Xx_NEWLINE_xXPre-existing neutropenia or neutrophil qualitative or quantitative disorderXx_NEWLINE_xXIndividuals with the following characteristics will be excluded: male breast cancer survivors, non-ambulatory, unable to provide informed consent; have a major mental illness (i.e., schizophrenia); have a mental illness that is not being treated/controlled (i.e., bipolar disorder); and reside > 100 miles from the research siteXx_NEWLINE_xXPatients who have ever been diagnosed with bipolar disorder or schizophreniaXx_NEWLINE_xXMajor mental illness (e.g., schizophrenia, major depressive disorder)Xx_NEWLINE_xXPresence of active malabsorption disorder (e.g., flare episodes documented within the preceding 3 months, presence of symptoms requiring daily medications for control) or history of extensive small bowel resectionXx_NEWLINE_xXSignificant physiological or psychological impairment that interferes with participation (e.g., migraines, bipolar disorder, psychosis, seasonal affective disorder)Xx_NEWLINE_xXNeurologic disorder that impairs ambulation (e.g. Parkinson’s)Xx_NEWLINE_xXPsychiatric disorder which would render the subject unable to provide informed consentXx_NEWLINE_xXPatients who have any major psychiatric diagnoses or thought disorder (e.g. schizophrenia, bi-polar disorder, dementia)Xx_NEWLINE_xXMedical record documentation of severe mental illness (i.e., schizophrenia or bipolar disorder), active suicidal ideation, or active substance use disorderXx_NEWLINE_xXHas a Diagnostic and Statistical Manual (DSM) IV diagnosis of Major Depressive DisorderXx_NEWLINE_xXSubstance use disorder within the prior six monthsXx_NEWLINE_xXAny disorder that would predispose the participant to seizuresXx_NEWLINE_xXCognitive or psychiatric disorder that would interfere with ability to provide informed consent or answer survey questions reliably\r\n* Any of these Diagnostic and Statistical Manual-5 (DSM-5) cognitive and psychiatric disorders would make someone ineligible: bipolar; delusional; dissociative; intellectual developmental; neurocognitive; psychotic; schizophreniform, schizophrenia, and schizoaffectiveXx_NEWLINE_xXHistory of marked anxiety disorder, or history of substance abuseXx_NEWLINE_xXPatients who have ever been diagnosed with bipolar disorder or schizophrenia.Xx_NEWLINE_xXPsychiatric disorder such as severe depression, manic depressive disorder, obsessive compulsive disorder or schizophrenia; (defined per medical history)Xx_NEWLINE_xXHave schizophrenia or any other psychotic disorderXx_NEWLINE_xXHave a diagnosed sleep disorder including untreated obstructive sleep apnea, periodic limb movement disorder, or restless leg syndromeXx_NEWLINE_xXHistory of oropharyngeal swallowing disorder prior to cancer diagnosisXx_NEWLINE_xXPre-existing active or untreated immunodeficiency disorder and/or chronic use of systemic steroidsXx_NEWLINE_xXDiagnosis of a formal thought disorder (e.g., schizophrenia)Xx_NEWLINE_xXKnown history of a neurological and/or psychological disorder that in the physician’s opinion may interfere with the patient’s ability to cooperate with study proceduresXx_NEWLINE_xXA principal diagnosis of major depressive disorder (MDD)Xx_NEWLINE_xXHistory of bipolar affective disorder or psychosisXx_NEWLINE_xXMedical history of cancer other than colorectal cancer or non-melanoma skin cancer, untreated or unstable mental or psychiatric disorder, learning disability, traumatic brain injury, drug or alcohol abuse, debilitating medical disorder such as advanced cardiac, respiratory or renal diseaseXx_NEWLINE_xXPsychiatric disorders or conditions that would preclude participation in the study intervention (e.g., untreated major depression or psychosis, substance abuse, severe personality disorder)Xx_NEWLINE_xXTreatment with other stimulant medications within 14 days of registration; however, a diagnosis of attention-deficit hyperactivity disorder (ADHD) does NOT exclude a child from participationXx_NEWLINE_xXSerious psychiatric disease including schizophrenia, bipolar disorder and severe depressionXx_NEWLINE_xXPatients must not have any contraindicated concurrent illnesses listed on the duloxetine package insert including:\r\n* Current primary psychiatric diagnosis (schizophrenia, psychosis) or suicidal ideation, history of bipolar disorder, or seizure disorder\r\n* History of alcohol or other substance abuse or dependence within 365 days prior to registration\r\n* Chronic liver disease\r\n* End-stage renal disease\r\n* Uncontrolled narrow-angle glaucoma\r\n* Clinically significant coagulation disorderXx_NEWLINE_xXMajor psychiatric disorder (e.g., psychosis, personality disorder)Xx_NEWLINE_xXPatients who have significant personality disorders or unstable psychiatric disorders (including active major depression, substance abuse, psychosis or bipolar disorder) as assessed by the interviewing clinicianXx_NEWLINE_xXPersonal history of an eating disorderXx_NEWLINE_xXOther serious, uncontrolled medical disorder, non-malignant systemic disease, or active, uncontrolled infection (including uncontrolled human immunodeficiency virus [HIV], hepatitis B or C), or any psychiatric disorder that prohibits obtaining informed consentXx_NEWLINE_xXMajor mental illness (e.g, schizophrenia, major depressive disorder)Xx_NEWLINE_xXHistory of, or current symptoms of, serious psychiatric disorder requiring antipsychotic medications or hospitalization; mild depression or stable anti-depressants, and anti-seizure medications are acceptable; anti-anxiety medications may be acceptableXx_NEWLINE_xXA score above 45 on the Wender Utah Rating Scale for attention deficit disorder (ADD) (WURS)Xx_NEWLINE_xXPatients who have any major psychiatric diagnoses (e.g., schizophrenia, bipolar disorder)Xx_NEWLINE_xXSignificant uncontrolled psychiatric disorder (psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (dementia, cognitive impairment), which the treating clinician believes prohibits the ability to participate in study proceduresXx_NEWLINE_xXPsychiatric disorders or conditions that would preclude participation in the study intervention (e.g. untreated major depression or psychosis, substance abuse, severe personality disorder)Xx_NEWLINE_xXDiagnosis of a major depressive episode, an acute anxiety disorder, psychosis, post-traumatic stress disorder (PTSD), or schizophrenia as listed in the patient’s medical history per Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria in the chart and/or by self-report; assessing the concomitant medications will provide some insight into whether this needs further evaluationXx_NEWLINE_xXIndividuals with pre-existing neurological disorder (i.e. brain tumors, dementia, Parkinson’s disease, multiple sclerosis, seizure disorder) or diagnosed with metastasis cancerXx_NEWLINE_xXIndividuals with a current substance use disorder will also be excludedXx_NEWLINE_xXDocumented history of mental incapacitation or significant emotional or psychiatric disorder (i.e. bipolar, schizophrenia) that, in the opinion of the investigator, precludes study entry as these patients may not be able to cooperate with this slightly invasive procedure or with the data collection processXx_NEWLINE_xXCo-morbid delirium, dementia, or active and untreated psychotic, bipolar or substance-dependence disorder interfering with consentXx_NEWLINE_xXHistory of neurological/psychiatric disorder, including psychotic disorder or dementia, or any other reason, which in the opinion of the investigator makes adherence to a treatment or follow-up schedule unlikelyXx_NEWLINE_xXSignificant uncontrolled psychiatric disorder (psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (dementia, cognitive impairment), which the treating clinician believes prohibits informed consent or participation in the studyXx_NEWLINE_xXHistory or presence of any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, gynecological, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder that, in the opinion of the investigator, contraindicates participation.Xx_NEWLINE_xXUntreated endocrine abnormality, such as hypothyroidism, parathyroid hormone disorderXx_NEWLINE_xXSubject has previously been diagnosed with a serious immunodeficiency disorder.Xx_NEWLINE_xXPsychiatric disorder that would preclude study participationXx_NEWLINE_xXPatients with an identified familial hyperlipidemia disorder.Xx_NEWLINE_xXDiagnosis of a formal thought disorder (e.g., schizophrenia)Xx_NEWLINE_xXHistory of a neurological or psychological disorder that may interfere with the patient’s ability to cooperate with study proceduresXx_NEWLINE_xXPILOT PARTICIPANTS AND HEALTHY CONTROLS ONLY: Diagnosis of a formal thought disorder (e.g. schizophrenia)Xx_NEWLINE_xXParticipants with major depressive disorder and/or suicidal ideation as determined by PHQ-9Xx_NEWLINE_xXCurrent or past diagnosis of a major psychiatric disorder precluding adequate outcome responses such as schizophrenia, dementia, delirium etc. as recorded in the pre-operative recordXx_NEWLINE_xXPresence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) verified by medical record sufficient to preclude completion of the assessment measures, interview or informed consentXx_NEWLINE_xXParticipant has known sleep apnea or medically treated sleep disorder (e.g. restless leg syndrome)Xx_NEWLINE_xXParticipant has current major psychiatric illness (i.e. schizophrenia, bipolar disorder)Xx_NEWLINE_xXCurrently with a diagnosis of major depression, manic depressive disorder, obsessive-compulsive disorder, or schizophrenia)Xx_NEWLINE_xXCurrently with a diagnosis of major depression, manic depressive disorder, obsessive-compulsive disorder, or schizophreniaXx_NEWLINE_xXMental incapacitation or significant emotional or psychiatric disorder that, in the opinion of the investigator, precludes study entryXx_NEWLINE_xXKnown primary benign or malignant hematologic disorder which can cause anemia.Xx_NEWLINE_xXUse of medication for treatment of another sleep disorder, such as restless leg syndrome or narcolepsyXx_NEWLINE_xXuntreated alcohol or substance abuse or dependence, bipolar, or psychotic disorderXx_NEWLINE_xXmedical conditions such as seizure disorder, restless leg disorder, or Parkinson's diseaseXx_NEWLINE_xXMental incapacitation or significant emotional or psychological disorder that, in the opinion of the investigators, precludes study entryXx_NEWLINE_xXMajor mental illness (e.g., schizophrenia, psychotic disorder)Xx_NEWLINE_xXHistory of Post-traumatic Stress DisorderXx_NEWLINE_xXDiagnosis of psychiatric disorders of psychosis, schizophrenia, or bipolar disorderXx_NEWLINE_xXPatients have a known history of seasonal affective disorder or substance abuseXx_NEWLINE_xXPrevious diagnosis of radiosensitivity disorder (i.e., ataxia telangiectasia)Xx_NEWLINE_xXPrevious diagnosis of collagen vascular disorder or vasculitisXx_NEWLINE_xXPresence or recent history of any systemic disorder or conditions, such as:Xx_NEWLINE_xXPatients will be between 6 months and 4-years post radiation treatment; ongoing chemoprevention therapy is permissible; based on International Classification of Diseases (ICD)-10 proposed criteria, a diagnosis of CRF will require evidence from the history, physical exam, and laboratory findings that the fatigue is a consequence of cancer or cancer therapy and not primarily a consequence of comorbid psychiatric disorders (schizophrenia, depression, generalized anxiety disorder, bipolar disorder, dementia, delirium or obsessive–compulsive disorder [OCD])Xx_NEWLINE_xXEducational, psychiatric (untreated or poorly controlled schizophrenia, major depression, or bipolar disorder), or communication (language) barrier that would preclude accurate assessment of postoperative pain and/or ability to answer questionnaires (need to be able to read, comprehend, and answer questions)Xx_NEWLINE_xXCurrently in treatment for a major psychiatric disorderXx_NEWLINE_xXHistory of demyelinating disorderXx_NEWLINE_xXMental incapacitation or significant emotional or psychological disorder that, in the opinion of the investigators, precludes study entry (these patients may not be able to cooperate with this slightly invasive procedure or with the data collection process)Xx_NEWLINE_xXDiagnosis of major depressive episode, acute anxiety disorder, liver or kidney dysfunction (defined by SGOT and creatinine levels 1.5 x upper limit of normal) as listed in the patient’s medical history in the chart within the past year and by self reportXx_NEWLINE_xXPersonal history of any chronic gastrointestinal (GI) disorder (i.e., irritable bowel syndrome, colitis)Xx_NEWLINE_xXPatients must not have a serious psychiatric illness (e.g. lifetime bipolar disorder, schizophrenia or other psychosis, serious personality disorder, severe major depressive disorder or recent suicide or psychiatric hospitalization) (previous 12 months), or a history of an eating disorder (anorexia nervosa or bulimia nervosa)Xx_NEWLINE_xXThrombocytopenia (platelet count < 50 K) or coagulation disorder that would contraindicate intramuscular injectionXx_NEWLINE_xXAny neurologic or psychiatric disorderXx_NEWLINE_xXAny neurologic or psychiatric disorder except depression, anxiety, or attention-deficit disorder/attention-deficit hyperactivity disorderXx_NEWLINE_xXHistory of disordered eating as indicated by the Eating Disorder Examination Questionnaire (EDEQ)Xx_NEWLINE_xXAny serious or unstable medical/psychiatric disorder (including severe substance use disorders, other than tobacco use disorder) in the past month that may interfere with study performance based on principal investigator (PI) judgmentXx_NEWLINE_xXReports diagnosis of seizure disorder or a history of neurological illness or closed head injury that in the opinion of the principal investigator (PI) or designated expert(s) feels that it would affect the results of the electroencephalogram (EEG)Xx_NEWLINE_xXMajor depressive disorder in the last year requiring treatmentXx_NEWLINE_xXHistory of panic disorder, psychosis, bipolar disorder, or eating disordersXx_NEWLINE_xXReports diagnosis of seizure disorder or a history of neurological illness or closed head injury that\r\nin the opinion of the principal investigator (PI) feels that it would affect the results of the electroencephalogram (EEG)Xx_NEWLINE_xXPatients with serious, concomitant disorder, including active systemic infection, autoimmune disease, proven or suspected immunosuppressive disorder or any other major medical illnesses of the cardiovascular or respiratory system, concurrent malignancy except for nonmelanoma skin lesionsXx_NEWLINE_xXAny major thought disorder (e.g., schizophrenia, dementia)Xx_NEWLINE_xXUnstable medical conditions (such as unstable heart disease, uncontrolled hypertension, thyroid disease, diabetes, renal or liver impairment, glaucoma, or prostatic hypertrophy) or psychiatric condition (such as current major depression, history of schizophrenia or bipolar disorder, or current regular use of psychiatric medications such as major tranquilizers and antidepressantsXx_NEWLINE_xXA history of thromboembolic disorder or cerebral vascular diseaseXx_NEWLINE_xXHave current psychiatric disorders (i.e. major depression, bipolar, and/or psychotic disorders) or substance use disorder as determined by a psychiatric screener (Mini International Neuropsychiatric Interview [MINI])\r\n* Alcohol use disorder: current mild disorder is eligible; moderate disorder is eligible if in early remission (3-12 months); severe disorder, current or early remission, is not eligible\r\n* Substance use disorder is as follows: current disorder is not eligible; mild or moderate in early remission is eligible; severe disorder in early remission is not eligibleXx_NEWLINE_xXAny hematologic disorder involving platelets or clotting abnormalities or any condition requiring treatment with transfusions, anticoagulants except platelet inhibitors (NSAIDs as needed for pain are permitted)Xx_NEWLINE_xXEvidence of hematopoietic, cardiovascular, hepatic, renal, neurologic, psychiatric, dermatologic, immune disorder, or other disease that may interfere with assessment of safety or efficacy of vaccine activity as indicated in study objectivesXx_NEWLINE_xXHospitalization due to a psychiatric disorder in the past 3 yearsXx_NEWLINE_xXMust be underdoing allogeneic or autologous HCT for a malignant or non-malignant disorderXx_NEWLINE_xXSubjects with systemic autoimmune disorder;Xx_NEWLINE_xXParticipants considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection; examples include, but are not limited to, corrected QT interval (QTc) prolongation > 470 msec, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, unstable spinal cord compression (untreated and unstable for at least 28 days prior to study entry), superior vena cava syndrome, extensive bilateral lung disease with less than 20% predicted lung function by diffusion capacity of the lungs for carbon monoxide (DLCO) (lung diffusion capacity testing), or any psychiatric disorder that prohibits obtaining informed consentXx_NEWLINE_xXSignificant gastrointestinal disorder(s), in the opinion of the Principal Investigator, (e.g., Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection)Xx_NEWLINE_xXHistory of autoimmune disorder or any illness that requires therapy with chronic steroids or immunomodulatorsXx_NEWLINE_xXPsychiatric disorders or conditions that, in the opinion of the investigator, would preclude participation in the study intervention (e.g. untreated major depression or psychosis, substance abuse, severe personality disorder).Xx_NEWLINE_xXIs mentally incapacitated or has a significant emotional or psychiatric disorderXx_NEWLINE_xXSuffering from a severe psychiatric disorder (assessed using self-reporting history of psychiatric diagnosis during the phone screening) that would interfere with participationXx_NEWLINE_xXIrritable bowel syndrome, chronic constipation, functional bowel disorders, or colonic motility disorderXx_NEWLINE_xXMajor depressive disorder in the last year requiring treatmentXx_NEWLINE_xXHistory of panic disorder, psychosis, bipolar disorder, or eating disordersXx_NEWLINE_xXWith current diagnosis of major axis I psychiatric disorder (Diagnostic and Statistical Manual of Mental Disorders [DSM]-IV), major depression, bipolar disorder, or schizophrenia, as per medical records or patient reportXx_NEWLINE_xXWith history of a neurological disorder, neurodegenerative disease, or traumatic brain injury with loss of consciousness (> 60 minutes), as per medical records or patient reportXx_NEWLINE_xXSubject has an acute psychiatric disorder or is cognitively impairedXx_NEWLINE_xXHistory of neurological disease known to affect cognition prior to initiating chemotherapy (e.g., stroke, head injury with loss of consciousness of > 30 minutes, seizure disorder, demyelinating disorder, mental retardation, primary brain tumor, brain metastases, etc.)Xx_NEWLINE_xXCurrent or past major psychiatric illness (e.g., schizophrenia, bipolar affective disorder)Xx_NEWLINE_xXPreexisting language or developmental disorder that would limit ability to cooperate with testing (as determined by the P.I. or treating physician after interviewing potential subject and his/her family; for example, a child may be excluded if he/she has confirmed or suspected autism spectrum disorder, dysarthria, dyslexia, lisp, hypotonia, or other age inappropriate speech development)Xx_NEWLINE_xXAny known psychiatric disorder other than mild depression or anxiety that may affect adherence to the study requirements.Xx_NEWLINE_xXPresence of a genetic disorder other than NF1 that effects cognition or is associated with magnetic resonance (MR) imaging abnormalities (e.g. tuberous sclerosis)Xx_NEWLINE_xXActive or history of major psychiatric disorders such as schizophrenia, schizoaffective disorder, major affective disorder in mid-life, or treatment with electroconvulsive therapy (ECT) (mild depression that is well treated with stable dose of selective serotonin reuptake inhibitor [SSRI] antidepressants may be allowed)Xx_NEWLINE_xXAcute painful perianal disorderXx_NEWLINE_xXContraindications to TRUS/prostate biopsy (BX)\r\n* Currently on blood thinning agents (Plavix, Coumadin etc.) or bleeding disorder\r\n* Active urinary tract infection\r\n* Acute painful perianal disorder (i.e. rectal abscess)Xx_NEWLINE_xXKnown bleeding disorder that cannot be sufficiently corrected with co-fact or fresh frozen plasma (FFP)Xx_NEWLINE_xXNo findings of pancreatic disorder as documented by CT or MRI or EUSXx_NEWLINE_xXInclusion criterion for PC suspicious cohort * A EUS or ERCP is scheduled to suspected pancreatic disorder.Xx_NEWLINE_xXA known diagnosis of hemochromatosis, mitochondrial disorder, or iron overloadXx_NEWLINE_xXCannot eat normal table food by mouth; NOTE: patients with any form of feeding tube or a swallowing disorder are not eligibleXx_NEWLINE_xXHaving a history or presence of a significant psychiatric disorder or any other condition that, in the investigator’s judgment, would interfere with participation in the trialXx_NEWLINE_xXPatients suffering from a severe psychiatric disorder or condition that would significantly interfere with study participationXx_NEWLINE_xXPATIENTS: Significant uncontrolled psychiatric disorder (psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (dementia, cognitive impairment), which the treating clinician believes prohibits the ability to participate in study proceduresXx_NEWLINE_xXHistory of current oropharyngeal dysphagia unrelated to cancer diagnosis (e.g. dysphagia due to underlying neurogenic disorder) (Arm 3 only)Xx_NEWLINE_xXActive substance use disorder (diagnosed or strongly suspected) (Arm 4)Xx_NEWLINE_xXPatients suffering from a severe psychiatric disorder or condition that would significantly interfere with study participation, as determined by the principal investigator or by the attending palliative care physicianXx_NEWLINE_xXA serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy in case re-initiation of dasatinib is needed.Xx_NEWLINE_xXHistory of parathyroid disorder or history or malignancy-associated hypercalcemia requiring therapy in the past 6 monthsXx_NEWLINE_xXPrevious history of a swallowing disorder, such as scleroderma, achalasia, esophageal stricture or esophageal diverticulumXx_NEWLINE_xXHistory or evidence of any psychiatric disorder, substance abuse or any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.Xx_NEWLINE_xXSerious concurrent uncontrolled medical disorder.Xx_NEWLINE_xXAny concomitant serious physical illness other than cancer (e.g., immune deficiency disease, bleeding disorder, etc.) within 1 year prior to dosing. No history of autoimmune disease.Xx_NEWLINE_xX